Project Grant R41HL147737

This $299,790 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel allosteric modulators of the thrombin receptor, protease-activated receptor 1 (PAR1), called Parmodulins, for the treatment of sickle cell disease (SCD). The project aims to identify optimized Parmodulins with improved potency and oral activity, and confirm their efficacy in mouse models of SCD, including...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,829,965.51 to support a randomized, double-blind, placebo-controlled Phase 2 clinical trial of intravenous citrulline for vaso-occlusive crisis in sickle cell disease. The goal is to evaluate whether the administration of citrulline, which plays a role in nitric oxide production, can shorten hospital length of stay and decrease opioid...

This $306,656 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of new biotechnological approaches to expeditiously synthesize heparin-like anticoagulants using engineered microbial cellular factories. The project aims to provide an alternative, reliable drug production process for heparin, a critical medicine used to treat thrombosis and other clotting disorders, which face...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to characterize the role of Factor XII (FXII) in the thrombo-inflammatory complications of sickle cell disease (SCD). The $1,449,454 award to the University of North Carolina at Chapel Hill (UNC-CH) will fund research to: 1) identify disease-specific triggers of FXII activation, 2) characterize FXII effects on neutrophil...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...

This National Heart, Lung, and Blood Institute (NHLBI) Project Grant award under the Cardiovascular Diseases Research program (CFDA 93.837) provides $156,340.00 to the Connecticut Children's Medical Center to develop and test a communication-enhancement intervention for healthcare providers (HCPs) to improve health outcomes in pediatric sickle cell disease (SCD). The 5-year grant will fund research activities including literature reviews, qualitative research with adolescent SCD patients and...

This National Heart, Lung, and Blood Institute (NHLBI) Project Grant under CFDA 93.837 - Cardiovascular Diseases Research program provides $202,366 in funding to Emory University to investigate the role of heme-induced complement activation in sickle cell disease (SCD) pregnancy. The research aims to characterize the effects of SCD and heme-induced complement activation on pregnancy outcomes in a preclinical mouse model (Aim 1), and determine if heme and/or complement modulation can improve...

The National Center for Complementary and Integrative Health (NCCIH) awarded a $963,947 Cooperative Agreement under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to the University of California, Irvine (UCI) to establish the Sickle Cell Disease Pain Analgesia and Integrative Network (SCDPAIN). This network aims to advance scientific understanding of pain mechanisms in sickle cell disease (SCD) through a collaborative, multidisciplinary research approach....

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), will fund a research study to investigate sex and gender influences on inflammation and pain in sickle cell disease. The award, valued at $496,503, will be administered by The Trustees of the University of Pennsylvania (the Awardee) from September 1, 2024 to July 31, 2028. The study has two main objectives: 1) to ascertain sex- and...

Novelmed Therapeutics, Inc. was awarded a $1,599,495 Project Grant from the National Heart, Lung and Blood Institute of the Department of Health and Human Services. The grant falls under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. Novelmed will use the funding to develop a novel disease-modifying treatment for paroxysmal nocturnal hemoglobinuria (PNH). The company's lead drug candidate selectively inhibits the alternative pathway of...